PBRM1 encodes a subunit of the PBAF (polybromo-associated BAF) chr3 remodeling complex, a specialized variant of the SWI/SNF complex that regulates gene transcription through ATP-dependent nucleosome remodeling 1. As a tumor suppressor gene, PBRM1 loss-of-function mutations are frequently found in clear cell renal cell carcinoma (ccRCC) and have significant clinical implications 23. Mechanistically, PBRM1 deficiency alters global transcriptional programs, particularly affecting JAK-STAT, hypoxia, and immune signaling pathways 2. In ccRCC, PBRM1 mutations paradoxically associate with improved response to immune checkpoint inhibitors targeting PD-1/PD-L1, with clinical benefit observed in patients harboring PBRM1 loss-of-function mutations 24. These tumors also correlate with high angiogenesis gene expression and improved outcomes with angiogenesis blockade therapies 5. The protein can be therapeutically targeted through PROTAC degraders that simultaneously degrade PBRM1 along with SMARCA2/4 ATPase subunits, inducing anti-proliferative effects in cancer cells 6. PBRM1 mutations represent actionable targets for personalized neoantigen vaccines, demonstrating that driver mutations can generate effective T cell responses against tumors 7.